WCP
VKTX icon

Wick Capital Partners’s Viking Therapeutics VKTX Stock Holding History

Wick Capital Partners’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$500K Buy
4,775
+1,106
+30% +$35.7K 0.08% 103
2026
Q1 		$270K Buy
3,669
+387
+12% +$12.4K 0.05% 172
2025
Q4 		$234K Buy
+3,282
New +$116K 0.04% 180

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Wick Capital Partners's VKTX Position: Q2 2026 in Review

Wick Capital Partners increased its Viking Therapeutics (VKTX) stake by 30% in Q2 2026, buying an estimated $35.7K and bringing the position to 4,775 shares worth $500K. The position accounts for 0.08% of the portfolio, ranked #103.

Wick Capital Partners first reported a position in VKTX in Q4 2025 and has held it in 3 quarters since. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Wick Capital Partners held 4,775 shares of Viking Therapeutics worth $500K as of Q2 2026.
  • Wick Capital Partners bought 1,106 Viking Therapeutics shares in Q2 2026, an estimated $35.7K.
  • Viking Therapeutics made up 0.08% of Wick Capital Partners's portfolio in Q2 2026, its #103 holding.
  • Wick Capital Partners first reported a position in Viking Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Wick Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.